A high-risk clinical-stage biotech firm leveraging significant R&D spending to advance proprietary drug candidates while managing substantial cash burn and negative shareholder equity.
Investors may view the company as a high-upside play if its oncology drug candidates successfully advance through clinical trials and secure approval; The substantial cash burn suggests management is aggressively pursuing growth, potentially leading to significant value creation upon success; Strategic collaborations provide immediate revenue visibility without full capital expenditure burden.
The company faces imminent liquidity challenges with only $3.3M in cash against a $25.9M annual cash burn rate requiring repeated dilutive equity raises; Negative shareholder equity of $26.1M and a retained earnings deficit of $229.5M indicate deep financial distress and potential for restructuring; Lack of profitable operations and dependence on external funding makes the stock highly volatile and speculative.
VolitionRX Ltd. is a clinical-stage biotechnology company developing novel drug candidates, primarily focusing on oncology and immunology, with operations centered in Canada and strategic partnerships for global development.
Despite a significant operating loss of $27.0M and negative cash flow from operations, the company maintained its research and development spend at $14.4M while reducing accounts receivable by $132k, indicating active pipeline management. The firm relied heavily on capital raising activities, generating $8.6M from common share issuances and $1.4M from debt to offset the net cash outflow of $17.5M.
The biotechnology sector is characterized by high capital intensity, long development cycles, and binary outcomes where successful drug launches can yield massive returns but failure results in total loss of invested R&D capital. Oncology remains a dominant therapeutic area with significant unmet medical needs driving competition among major pharmaceutical players and smaller biotech firms.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $306.4K | $775.3K | $1.2M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $306.4K | $775.3K | $1.2M |
| Operating Expenses | $32.1M | $36.8M | $28.3M |
| Operating Income | $-31.8M | $-36.0M | $-27.0M |
| R&D | $14.6M | $19.6M | $14.4M |
| G&A | $10.9M | $10.4M | $8.5M |
| Marketing | $6.6M | $6.8M | $5.4M |
| Stock-Based Comp | $0 | $2.3M | $1.3M |
| D&A | $936.1K | $1.2M | $1.1M |
| Depreciation | $865.3K | $1.1M | $1.1M |
| Amortization | $75.6K | $84.9K | $0 |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $125.3K | $93.3K | $9.9K |
| Pre-Tax Income | $-31.8M | $-36.0M | $-27.0M |
| Income Tax | $-1.2M | $-310.6K | $233.0K |
| Continuing Ops | $-30.6M | $-35.7M | $-27.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-30.6M | $-35.7M | $-27.3M |
| Minority Interest | $0 | $0 | $-290.1K |
| Net to Common | $-30.6M | $-35.7M | $-27.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.2M | $21.9M | $4.1M |
| Cash & Equivalents | $10.9M | $20.7M | $3.3M |
| Accounts Receivable | $72.6K | $242.6K | $110.6K |
| Other Current Assets | $1.2M | $881.5K | $681.8K |
| Long-Term Assets | $6.1M | $6.1M | $5.3M |
| PP&E (Net) | $5.4M | $5.5M | $4.4M |
| Intangibles | — | $23.9K | — |
| Operating Leases | $619.4K | $549.5K | $599.8K |
| Other LT Assets | $110.5K | $0 | $313.7K |
| Total Assets | $18.3M | $28.0M | $9.4M |
| Current Liabilities | $17.4M | $31.8M | $7.8M |
| Accounts Payable | $3.0M | $3.2M | $2.8M |
| Current Debt | $1.1M | $1.2M | $860.2K |
| Current Leases | $245.2K | $199.3K | $221.8K |
| Deferred Revenue | — | — | $97.9K |
| Other Current Liab | $10.2M | $23.3M | $367.8K |
| Long-Term Liabilities | $4.0M | $4.8M | $27.7M |
| Long-Term Debt | $2.8M | $3.6M | $4.0M |
| LT Operating Leases | $400.1K | $378.1K | $410.7K |
| Other LT Liab | $856.6K | $822.7K | $23.4M |
| Total Liabilities | $21.4M | $36.7M | $35.5M |
| Shareholders' Equity | $-3.1M | $-8.7M | $-26.1M |
| Paid-In Capital | $164.4M | $194.4M | $204.2M |
| Retained Earnings | $-167.3M | $-202.6M | $-229.5M |
| AOCI | $227.1K | $243.9K | $385.6K |
| Total L&E | $18.3M | $28.0M | $9.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-30.6M | $-35.7M | $-27.3M |
| Non-Cash Adjustments | $4.1M | $3.5M | $3.3M |
| Working Capital Changes | $11.2M | $14.1M | $-1.9M |
| Cash from Operations | $-15.3M | $-18.1M | $-25.9M |
| Capital Expenditures | $1.6M | $1.1M | $277.5K |
| Cash from Investing | $-1.6M | $-1.1M | $-573.9K |
| Debt Issuances | — | $1.9M | $1.4M |
| Debt Repayments | — | $981.3K | $1.1M |
| Share Buybacks | — | $31.8K | $0 |
| Cash from Financing | $6.9M | $29.0M | $8.7M |
| FX Effect | $195.6K | $27.0K | $344.7K |
| Net Change in Cash | $-9.7M | $9.9M | $-17.5M |
| Beginning Cash | $20.6M | $10.9M | $20.7M |
| Ending Cash | $10.9M | $20.7M | $3.3M |
The company's revenue is derived from collaborative arrangements and milestone payments related to its oncology and immunology drug candidate programs, supported by research and development expenses of $14.4M in 2024.
Substantial cash burn of $25.9M in 2024 threatening liquidity given limited cash reserves of $3.3M; Heavy reliance on external financing via equity issuances to fund operations; High probability of failure associated with late-stage clinical trials for oncology drugs; Significant negative accumulated retained earnings deficit exceeding $229M.
Access to proprietary novel drug targets with potential for high-value market exclusivity; Strategic partnerships that share development risk and cost; Experienced management team focused on advancing clinical pipelines through key regulatory milestones.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.